Przejdź do zawartości

β-talasemia intermedia i minor

Leczenie podtrzymujące

Chelatacja żelaza

Iron out for nontransfused thalassemia. (opens new window)

Marks PW.

Źródło‎: Blood 2012;120(5):928-9.

Indeks‎: PubMed 22859709

DOI‎: 10.1182/blood-2012-06-433227

https://www.ncbi.nlm.nih.gov/pubmed/22859709 (opens new window)

Iron overload in β-thalassemia intermedia: an emerging concern. (opens new window)

Musallam KM, Cappellini MD, Taher AT.

Źródło‎: Curr Opin Hematol 2013;20(3):187-92.

Indeks‎: PubMed 23426199

DOI‎: 10.1097/MOH.0b013e32835f5a5c

https://www.ncbi.nlm.nih.gov/pubmed/23426199 (opens new window)

Suplementy diety i inne terapie podtrzymujące

Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. (opens new window)

Anthi A, Tsangaris I, Hamodraka ES, Lekakis J, Armaganidis A, Orfanos SE.

Źródło‎: Blood 2012;120(7):1531-2.

Indeks‎: PubMed 22899478

DOI‎: 10.1182/blood-2012-04-422568

https://www.ncbi.nlm.nih.gov/pubmed/22899478 (opens new window)

Prevalance of iron deficiency in thalassemia minor: a study from tertiary hospital. (opens new window)

Dolai TK, Nataraj KS, Sinha N, Mishra S, Bhattacharya M, Ghosh MK.

Źródło‎: Indian J Hematol Blood Transfus 2012;28(1):7-9.

Indeks‎: PubMed 23449336

DOI‎: 10.1007/s12288-011-0088-9

https://www.ncbi.nlm.nih.gov/pubmed/23449336 (opens new window)

Therapeutic roles of curcumin: lessons learned from clinical trials. (opens new window)

Gupta SC, Patchva S, Aggarwal BB.

Źródło‎: AAPS J 2013;15(1):195-218.

Indeks‎: PubMed 23143785

DOI‎: 10.1208/s12248-012-9432-8

https://www.ncbi.nlm.nih.gov/pubmed/23143785 (opens new window)

Vitamin E supplement improves erythrocyte membrane fluidity of thalassemia: an ESR spin labeling study. (opens new window)

Sutipornpalangkul W, Morales NP, Unchern S, Sanvarinda Y, Chantharaksri U, Fucharoen S.

Źródło‎: J Med Assoc Thai 2012;95(1):29-36.

Indeks‎: PubMed 22379738

https://www.ncbi.nlm.nih.gov/pubmed/22379738 (opens new window)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. (opens new window)

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD.

Źródło‎: Am J Hematol 2013;88(6):503-6.

Indeks‎: PubMed 23553596

DOI‎: 10.1002/ajh.23445

https://www.ncbi.nlm.nih.gov/pubmed/23553596 (opens new window)